Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
Background Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice. M...
Main Authors: | Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andreas, Yirong Wang, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Rajan Gupta, Jason Zhu, Matthew Labriola, Shannon McCall, Daniel J. George, Pooja Ghatalia, Farshid Dayyani, Robert Edwards, Michelle S Park, Rajbir Singh, Robin Jacob, Saby George, Bo Xu, Matthew Zibelman, Razelle Kurzrock, Carl Morrison |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1773200 |
Similar Items
-
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
by: Saby George, et al.
Published: (2018-12-01) -
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01) -
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
by: Amélie Boichard, et al.
Published: (2017-03-01) -
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond
by: Benjamin Miron, et al.
Published: (2020-11-01) -
PD-L1 Expression in Mastocytosis
by: Margaret Williams, et al.
Published: (2019-05-01)